leflunomide has been researched along with Aortic Arteritis, Giant Cell in 12 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission." | 8.12 | Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study. ( Das, S; Datta, A; Ghosal, A; Goswami, RP; Sarkar, S; Sinha, D, 2022) |
| " This report aims to assess the effectiveness and safety of leflunomide (LEF) in Takayasu arteritis (TA) and giant cell arteritis (GCA)." | 5.41 | Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies. ( Brugarolas, E; Estrada, P; LLop, D; Maymó-Paituvi, P; Narváez, J; Nolla, JM; Palacios-Olid, J; Vidal-Montal, P, 2023) |
| " Results of in-vitro studies on Janus kinase (JAK)/signal transducers and activators of transcription and mammalian target of rapamycin (mTOR) pathways, comparative studies with leflunomide as an induction therapy, and a long-term follow-up study with tocilizumab may contribute to the management of Takayasu arteritis." | 5.12 | Aortitis: an update. ( Erdogan, M, 2021) |
| "To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission." | 4.12 | Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study. ( Das, S; Datta, A; Ghosal, A; Goswami, RP; Sarkar, S; Sinha, D, 2022) |
| "Treatment with leflunomide or low doses of glucocorticoids were not associated with severe course in our cohort." | 2.82 | COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. ( Hočevar, A; Ješe, R; Kramarič, J; Rotar, Ž; Tomšič, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, S | 1 |
| Goswami, RP | 1 |
| Sinha, D | 1 |
| Ghosal, A | 1 |
| Datta, A | 1 |
| Sarkar, S | 1 |
| Kramarič, J | 1 |
| Ješe, R | 2 |
| Tomšič, M | 2 |
| Rotar, Ž | 2 |
| Hočevar, A | 2 |
| Narváez, J | 1 |
| Estrada, P | 1 |
| LLop, D | 1 |
| Vidal-Montal, P | 1 |
| Brugarolas, E | 1 |
| Maymó-Paituvi, P | 1 |
| Palacios-Olid, J | 1 |
| Nolla, JM | 1 |
| Sebastian, A | 2 |
| Kayani, A | 2 |
| Dasgupta, B | 3 |
| Erdogan, M | 1 |
| Tomelleri, A | 1 |
| Coath, F | 1 |
| Prieto-Pena, D | 1 |
| Mo, J | 1 |
| Tengesdal, S | 1 |
| Diamantopoulos, AP | 2 |
| Myklebust, G | 2 |
| Samson, M | 1 |
| Greigert, H | 1 |
| Ghesquière, T | 1 |
| Bonnotte, B | 1 |
| Hetland, H | 1 |
| Adizie, T | 1 |
| Christidis, D | 1 |
| Dharmapaliah, C | 1 |
| Borg, F | 1 |
| Unizony, S | 1 |
| Stone, JH | 1 |
| Stone, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica[NCT03576794] | Phase 3 | 94 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for leflunomide and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.
Topics: Cardiovascular Diseases; COVID-19; Giant Cell Arteritis; Glucocorticoids; Humans; Hypertension; Lefl | 2022 |
Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Topics: Antirheumatic Agents; Cohort Studies; Giant Cell Arteritis; Glucocorticoids; Humans; Leflunomide; Me | 2023 |
Aortitis: an update.
Topics: Antibodies, Monoclonal, Humanized; Aorta; Aortitis; Female; Follow-Up Studies; Giant Cell Arteritis; | 2021 |
[Treatment of giant cell arteritis].
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Azat | 2019 |
New treatment strategies in large-vessel vasculitis.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Arteritis; Giant Cell Art | 2013 |
7 other studies available for leflunomide and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study.
Topics: Follow-Up Studies; Giant Cell Arteritis; Humans; Leflunomide; Prednisolone; Recurrence; Steroids | 2022 |
Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters.
Topics: Aged; Female; Fluorodeoxyglucose F18; Giant Cell Arteritis; Humans; Laboratories; Leflunomide; Posit | 2021 |
Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis: A Single-Center, 10-Year Experience.
Topics: Giant Cell Arteritis; Humans; Leflunomide; Takayasu Arteritis | 2022 |
Does leflunomide have a role in giant cell arteritis? An open-label study.
Topics: Aged; Drug Therapy, Combination; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Immunosuppre | 2019 |
Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival.
Topics: Aged; Antirheumatic Agents; Dose-Response Relationship, Drug; Drug Monitoring; Female; Giant Cell Ar | 2019 |
Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
Topics: Adrenal Cortex Hormones; Aged; Female; Giant Cell Arteritis; Giant Cells; Humans; Isoxazoles; Leflun | 2013 |
Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; Female; Giant Cell Arteritis; H | 2012 |